|
Market Closed -
Nasdaq
02:30:00 06/01/2026 am IST
|
5-day change | 1st Jan Change | ||
| 4.660 USD | -0.21% |
|
-.--% | +3.10% |
| 15/04 | Evotec Taps CureVac Executive as COO | MT |
| 06/01 | CureVac ends coverage after BioNTech acquisition |  |
| Market Cap | 87Cr 99Cr 82Cr 74Cr 139.26Cr 9.54TCr 139.84Cr 980.48Cr 378.36Cr 4.85TCr 373.44Cr 365.15Cr 16TCr | P/E 2023 |
-3.23x | P/E 2024 | 4.57x |
|---|---|---|---|---|---|
| Enterprise Value | 42Cr 49Cr 40Cr 36Cr 68Cr 4.67TCr 68Cr 479.67Cr 185.1Cr 2.37TCr 182.7Cr 178.64Cr 7.63TCr | EV / Sales 2023 |
9.16x | EV / Sales 2024 | 0.55x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: CureVac
| 1 day | -0.21% | ||
| Current year | +3.10% |
| Current year | 4.48 |  | 4.68 |
| 1 year | 4 | | 5.55 |
| 3 years | 2.22 | | 7.7 |
| 5 years | 2.22 | | 58.36 |
| 10 years | 2.22 | | 151.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 28/03/2023 | |
Myriam Mendila
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Malte Greune
COO | Chief Operating Officer | 61 | 01/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 01/08/2015 | |
Mathias Hothum
BRD | Director/Board Member | 58 | 01/08/2015 |
| Director/Board Member | 69 | 22/06/2022 |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 5.38Cr 6.16Cr 5.08Cr 4.61Cr 8.64Cr 591.55Cr 8.67Cr 61Cr 23Cr 300.75Cr 23Cr 23Cr 967.71Cr | 54Cr 61Cr 51Cr 46Cr 86Cr 5.89TCr 86Cr 605.32Cr 233.59Cr 2.99TCr 230.55Cr 225.43Cr 9.63TCr |
| Net income | -26Cr -30Cr -25Cr -22Cr -42Cr -2.86TCr -42Cr -294.26Cr -113.55Cr -1.46TCr -112.08Cr -109.59Cr -4.68TCr | 16Cr 19Cr 15Cr 14Cr 26Cr 1.78TCr 26Cr 183.44Cr 71Cr 907.37Cr 70Cr 68Cr 2.92TCr |
| Net Debt | -36Cr -41Cr -34Cr -31Cr -58Cr -3.97TCr -58Cr -407.89Cr -157.4Cr -2.02TCr -155.36Cr -151.91Cr -6.49TCr | -44Cr -51Cr -42Cr -38Cr -71Cr -4.87TCr -71Cr -500.81Cr -193.26Cr -2.48TCr -190.75Cr -186.51Cr -7.97TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CVAC Stock
Select your edition
All financial news and data tailored to specific country editions
